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Summary 
The immunosuppressant hormone dexamethasone  (Dex) interferes with T cell-specific signals 
activating the enhancer sequences directing interleukin 2 (IL-2) transcription. We report that 
the Dex-dependent downregulation of 12-O-tetradecanoyl-phorbo1-13-acetate (TPA) and calcium 
ionophore-induced activity of the I1,2 enhancer are mediated by glucocorticoid receptor (GR) 
via  a  process  that  requires  intact  NH2-  and COOH-terminal  and DNA-binding domains. 
Functional analysis of chloramphenicol acetyltransferase  (CAT) vectors containing internal ddetions 
of the -317 to + 47 bp I1,2 enhancer showed that the GR-responsive elements mapped to regions 
containing nuclear factor of activated T cells protein (NFAT) (- 279 to - 263 bp) and AP-1 (- 160 
to - 150 bp) motifs. The AP-1 motif binds TPA and calcium ionophore-induced nuclear factor(s) 
containing los protein. TPA and calcium ionophore-induced transcriptional  activation of homo- 
oligomers of the NFAT dement were not inhibited by Dex, while AP-1 motif concatemers were 
not  stimulated by TPA and calcium ionophore.  When combined, NFAT  and AP-1 motifs 
significantly synergized in directing CAT transcription.  Such a synergism was impaired by specific 
mutations affecting the tram-acting factor binding to either NFAT or AP-1 motifs. In spite of 
the lack of hormone regulation of isolated c/s dements, TPA/calcium ionophore-mediated activation 
of CAT vectors containing a combination of the NFAT and the AP-1 motifs became suppressible 
by Dex. Our results show that the IL-2-AP-1 motif confers GR sensitivity to a flanking region 
containing a NFAT dement and suggest that synergistic cooperativity between the NFAT and 
AP-1 sites allows GR to mediate the Dex inhibition of I1`2 gene transcription.  Therefore,  a 
Dex-modulated second level of II:2 enhancer regulation, based on a combinatorial modular interplay, 
appears to be present. 
I 
'mmunosuppression by physiological and pharmacological 
agents (i.e., glucocorticoids,  cyclosporin A, and FK-506) 
plays a key role in controlling immune reactions against en- 
dogenous or exogenous  antigens  and has been reported to 
be very effective in induction of transplantation  tolerance (1). 
Most of the immunosuppressants  affect the cascade of mo- 
lecular events arising from the interaction of the antigen with 
the TCR or from other costimulatory agents that turn on 
the transcription of specific lymphokine genes such as I1`2 
(1-6).  I1,2 is the major growth factor for T  lymphocytes, 
which is involved in T cell differentiation,  functional activa- 
tion, and proliferation  (7, 8). Besides being widely used as 
therapeutical agents, ghcocorticoid hormones are physiological 
immunosuppressants  suggested to be involved in the control 
of immune and inflammatory hyper-reactivity during the stress 
response (9). We have previously reported that glucocorti- 
coid hormones inhibit phorbol ester and calcium ionophore-in- 
duced transcription  of the human I1`2 gene (10). We have 
also shown that such a glucocorticoid inhibition was not ob- 
served in fibroblasts expressing a transfected II,2 gene, in- 
cluding 2.0 kb of 5' flanking regulatory sequences, suggesting 
that the hormone interferes with T  cell-specific activating 
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gene arise from interaction of the antigen with the TCR in 
combination with other costimulatory  elements  and subse- 
quent activation of protein kinase C and intraceUular  calcium 
increase, which in turn activate the synthesis or the function 
of a set of tram-acting factors binding to consensus sequences 
in the 5' flanking region of the gene (6, 13-21). Several puta- 
tive enhancer cis elements have been identified in the  -300 
bp region of the gene, including two AP-l-like and octamer 
motifs, AP-3 and NFkB dements, a purine-rich  region binding 
a less identified protein called nudear  factor of activated T 
ceils (NFAT), 1 and a more recently reported CD28-respon- 
sire dement (13-21). All of these c/s elements are suggested 
to cooperate with each other to compose the overall IL-2 en- 
hancer  activity (14).  These observations raise  the  question 
of how interference with  such a transcriptional  regulatory 
activity by immunosuppressive agents might  occur.  In this 
regard, glucocorticoid hormones are particularly interesting 
as agents potentially interfering  with Ib2 enhancer  tram-acting 
factors. Indeed, glucocorticoid hormones are known to con- 
trol gene expression by activating intracellular receptors be- 
longing to the steroid/thyroid hormone/retinoic acid receptor 
superfamily of nudear  trans-acting  factors,  which binds  to 
specific  consensus sequences provided of intrinsic  enhancer 
properties (reviewed in reference 22). This suggests that the 
hormone-receptor complex might act at or proximal to the 
transcriptional  steps involved in Ib2 gene expression. How- 
ever, in contrast to results described for Ib2 gene inhibition 
by another immunosuppressant agent, cyclosporin A (23-25), 
the synthetic glucocorticoid hormone dexamethasone (Dex) 
has been recently reported not to affect the levels of the known 
IL-2 gene trans-acting  factors (26).  To study the molecular 
events implicated in the Dex-induced downregnlation of the 
Ib2 enhancer,  we delineated both the glucocorticoid receptor 
(GK) domains  and the Ib2 c/s-regnlatory  sequences medi- 
ating the hormone action.  We report here that  the GK, by 
a process that requires the presence of intact NH2-terminal, 
COOH-terminal, and DNA-binding domains, selectively im- 
pairs the synergistic cooperativity of two distinct c/s elements, 
the NFAT and AP-1 motifs, while it does not affect the en- 
hancer activities of these isolated regnlatory sequences. Our 
data suggest a novel mechanism of interference with a cooper- 
ative regulatory pathway of IL-2 enhancer c/s dements involving 
a second level of transcriptional  regulation based on combi- 
natorial  modular  interplay. 
Materials and Methods 
Plasmids.  The plasmid plL2CAT contains  the  -575 to  +47 
bp IL-2 flanking  region  driving  the expression of the chloram- 
phenicol-acetyl-transferase  (CAT)  gene  (27,  28).  Plasmids 
(-317/+ 47) IL-2CAT and the internal deletion mutants of the IL-2 
1  A bbreviations used in this  paper: CAT, chloramphenicol-acetyl-transferase; 
Dex, dexamethasone;  GALV,  gibbon  ape leukemia  virus; GR., glucocorticoid 
receptor; GRE, GR.-responsive  element; MMTV, mouse  mammary  tumor 
virus; NFAT,  nuclear factor  of activated  T cells; tk, thymidine  kinase; TPA, 
12-O-tetradecanoyl-phorbol-13-acetate. 
enhancer CAT vectors represented in Fig. 2 (a generous gift of Dr. 
G. R. Crabtree, Stanford University, Stanford, CA) have been de- 
scribed (14). CAT expression vectors containing concatemers of the 
IL-2 c/s elements were constructed  by inserting  into  the BamHI 
site of pBLCAT2 vector (29) (including the  -105 bp fragment of 
the thymidine kinase [tk] promoter, missing the octamer motif and 
driving CAT gene expression) three copies of either the IL-2-NFAT 
site (fragment  - 294 to  - 261 bp of the IL-2 enhancer, 3x[NFAT]- 
tk-CAT),  the Ib2-NFkB site (-210 to  -192 bp,  3x[NFkB]-tk- 
CAT), the distal and proximal IL2-AP-l-like motifs (- 188 to - 170 
bp and  -160 to  -139 bp, 3x[dAP-1]-tk-CAT and 3x[pAP-1]-tk- 
CAT, respectively), four copies of the proximal IL-2-octamer motif 
(fragment  -96 to  -66 bp, 4x[Oct]-tk-CAT),  and two copies of 
a synthetic oligonucleotide  spanning the  -294/-265  bp NFAT 
region fused to the  -160/-139 bp AP-1 motif (pNFAT-AP-I-tk- 
CAT). CAT expression vectors, containing concatemers of the mu- 
tated IL-2 cis elements (NFATm, APlml, and APlm2) were con- 
structed in a similar way after synthesis of corresponding oligonu- 
cleotides carrying  the mutations  indicated in figure legends. All 
of those multimers were constructed as synthetic oligonucleotides, 
including BamHI and BgllI restriction  sites at the 5' and 3' end, 
respectively. The plasmid p[- 575/+ 47]tk-CAT contains one copy 
of the IL-2 enhancer  -575 to  +47 bp fragment  cloned into  the 
HindlII site of pBLCAT2 in the antisense orientation with respect 
to CAT gene transcription.  GALV-AP-1-CAT  contains six copies 
of the Apol motif-containing core enhancer element of the SEATO 
strain of the gibbon ape leukemia virus (GALV) LTR. (30, 31). The 
plasmid MMTV-CAT  (containing  the LTR of the mouse mam- 
mary tumor virus) has been previously described (32). Wild-type 
(pRShGRcr and HG0) and mutant (HG3, HG8, I37, I204, I422, 
and I582) GR expression vectors (33, 34) were provided by Drs. 
R. Evans (The Salk Institute, La Jolla, CA) and P. Chambon (IN- 
SERM U.184, LGME-CNRS,  Strasbourg,  France). The plasmid 
pCH110 (Pharmacia, Uppsala, Sweden) contains a functional lacZ 
gene, coding for B-galactosidase, under the transcriptional control 
of the SV40 early promoter. 
Cell Culture and DNA  Transfections.  The human Jurkat  T cell 
line was cultured in RPMI 1640 supplemented with 10% FCS and 
antibiotics  (Flow  Laboratories,  Ayrshire,  Scotland).  Cells were 
treated with 30 ng/ml of 12-O-tetradecanoyl-phorbol-13-acetate 
(TPA), 1/~g/ml of A23187 (Sigma Chemical Co., St. Louis, MO), 
or 1.5 ~g/ml of ionomycin (Calbiochem-Behring Corp., San Diego, 
CA) in the presence  or in the absence  of 1/xM dexamethasone (Sigma 
Chemical Co.). 
Transfections of lymphoid cells were carried out by the DEAE 
dextran method (35) as described (10). Cells were cotransfected with 
various plasmids together  with pCH110  (as internal  control  for 
transfection efficiency). 24 h after transfection, cells were treated 
with the drugs indicated above, and after further  24 h, cells were 
harvested and protein extracts prepared for the CAT and/~-galacto- 
sidase assays. 
CAT Assay.  CAT assay  was carried out as previously described 
(36) by incubating  50-100 #g of cell lysate protein with 0.1/xCi 
[14C]chloramphenicol (sp act, 60 mCi/mmol;  Amersham  Corp., 
Arlington  Heights,  IL) in the presence of 9 mM acetyl-coenzyme 
A (Sigma Chemical Co.) for different times at 37~  Acetylated 
and unacetylated chloramphenicol were separated by TIC and acet- 
ylation  quantified  by  autoradiography  and  liquid  scintillation 
counting. 
fl-Galactosidase Assay.  A 20-30-/~g sample of the same cell ly- 
sate prepared for analysis of CAT activity was diluted in 100 mM 
NaPO4, 10 mM KC1, 1 mM Mg2SO4, 50 mM 3-mercaptoethanol, 
pH  7.0; and  B-galactosidase activity  was  determined  spectro- 
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D-galactoside. 
Gel Mobility Shift Assays.  Cells  were lysed in 10 mM Hepes 
(pH 7.9), 1.5 mM MgClz, 10 mM KC1, 0.25 mM dithiothreitol, 
0.5 mM PMSF, and nuclei were spun at 800 g and extracted in 
20 mM Hepes (pH 7.9), 20% glycerol, 0.42 M NaC1, 0.2 mM 
EDTA, 1.5 mM MgC12, 0.25 mM dithiothreitol, 0.5 mM PMSF. 
Nuclear extract was cleared  by centrifugation. Nuclear extracts (5 
#g of protein) were incubated for 20 min at 25~  in 15 #1 of reac- 
tion buffer containing 15 mM Hepes (pH 7.8), 70 mM NaC1, 0.5 
mM dithiothreitol, 2% glycerol, 2.5/~g of poly(dI-dC), and I ng 
of 32p-labeled IL-2-proximal  AP-1 probe (-160 to  -139) in the ab- 
sence or in the presence of a 10- or 100-fold excess of cold wild- 
type AP-1 or mutated AP-I-ml or AP-I-m2 oligonucleotide com- 
petitors. The sequences of the oligonucleotides  are as follows:  AP1, 
AAATTCCAAAGAGTCATCAGAA; APlml,  AAATTCCAA- 
AGAactgTCAGAA; APlm2,  gggcTCCAAAGAGTCATCAGAA. 
Protein-DNA complexes  were separated on 4% polyacrylamide  gels 
with 22.5 mM Tris-borate (pH 8.0) and 1 mM EDTA buffer. In 
gel retardation  experiments  using los- and B-galactosidase  antibodies, 
nuclear extracts were preincubated with the antibodies for 15 min 
at 25~  before performing the DNA binding reaction described 
above. A~nity-purified antibody to fos peptide (amino acids 129- 
153) (37) was kindly donated by Dr. Michael Iadarola (National 
Cancer Institute, Bethesda,  MD). A~nity-purified antibody against 
B-galactosidase was a gift of Dr. David Levens (National Cancer 
Institute) (38). 
Results 
Delineation of GR Domains Required  for IL.2 Enhancer Repres- 
sion.  We have  previously reported  that Dex inhibits the 
TPA/calcium ionophore-induced transcriptional activation 
from the  -575 to  +47 bp region of the IL-2 gene driving 
the expression of the CAT reporter (10). Inhibition of TPA/ 
calcium  ionophore-induced  activation  of  the  Ib2  en- 
hancer-CAT construct by Dex was strictly dependent on the 
presence of the cotransfected GR expression vector, suggesting 
that GR is involved in mediating the drug action on the II.,2 
enhancer (10). 
To delineate the GR domains involved in the repression 
of the Ib2 promoter activity, we studied the effects of several 
GR mutant expression vectors on the activity of the cotrans- 
fected plL2-CAT. Fig. 1 shows that GR mutants HG8, I204, 
and to a lesser extent I37, carrying ddetion (HG8) or muta- 
tions (I204  and I37)  of the NH2-terminal domain, respec- 
tively, have decreased Dex-mediated repression of the 11.-2- 
CAT expression.  Truncation of the COOH-terminal ligand 
binding domain (HG3) also impaired hormone-independent 
and -dependent repression  activity (Fig.  1). Mutation of the 
receptor DNA-binding domain (1422) resulting in the dis- 
ruption of the first  zinc finger structure also reduced the 
hormone-dependent inhibition of plL-2-CAT activity (Fig. 
1). The effects of GR mutations on the inhibition of the II.-2 
enhancer parallel those on the GR-responsive element (GILE) 
of the mouse mammary tumor virus (MMTV)-CAT vector, 
as far as the NH2-terminal and DNA-binding domains are 
concerned (Fig.  1).  In contrast,  deletion of the  COOH- 
terminal domain results in a hormone-independent constitu- 
tively active receptor tram-acting the MMTV-CAT expres- 
sion (Fig. 1). Transcriptional activity of GRE by GR has been 
shown to require the DNA-binding and NH2-terminal do- 
mains interacting with consensus sequence motif and other 
cooperating factors of the transcriptional machinery, respec- 
tively, being the COOH-terminal domain per se dispensable 
for trans-acting activity (33, 34, 39, 40). In contrast, our data 
show that the GR activity on the II:2 enhancer, besides the 
NH2 terminus and the DNA-binding region, also requires 
the COOH-terminal domain, suggesting that the receptor 
needs differential and/or potentially more complex interac- 
tions with the II.-2 transcriptional unit involving additional 
regions of GR. 
Delineation of GR-res~nsive Elements in the lb2 Enhanc~  To 
delineate the c/s regulatory elements of the II:2 gene whose 
transactivation by TPA and calcium ionophore is inhibited 
by Dex, we studied the drug effect on the expression of tran- 
siently transfected CAT vectors in which reporter gene tran- 
scription was directed by 5' deletion of the  -575  to  +47 
bp region of the I1.-2 gene or by the  -317 to  +47 bp frag- 
ment carrying several internal deletions. In agreement with 
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Figure 1.  Repression  of II.-2 en- 
hancer activity  by wild-type and 
mutant GR. Jurkat cells  were  trans- 
fected  with 2/~g of either MMTV- 
CAT or pIL-2-CAT reporter plas- 
mids in the absence or in the pres- 
ence of espression vectors (1 #g) 
producing either wild-type (WT; 
bar) or various mutant GR (HG8, 
I37, I204, I422, HG3, I582; solid 
lines). In WT GR, N and C indi- 
cate NH2  terminus and COOH 
terminus, and DNA indicates the 
DNA-binding domain.  The I series 
of GR mutants is characterized  by the insertion of three to four extra aminoacids in the positions indicated  by the mutant name and shown  by the 
arrows. The GR mutants I582 and HG3 are not able to bind the hormone. Half  of the transfected  cells were incubated in growth medium (shaded 
bars) and the other half in the presence of I/~M DEX (solid bars). CAT activity  was determined  24 h later and expressed as a percentage of either 
the activation  of MMTV-CAT (left) or the repression of the TPA/calcium  ionophore-induced  Ib2-CAT expression (right) relative to wild-type  GR- 
transfected cells. The results are representative of three experiments. 
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Figure 2.  (A) Schematic representation of 
"~--~  some  of  the  positive  transcriptional  c/s- 
regulatory elements in the 5' flanking region 
of the 11:2  gene. C/s elements implicated  in I1:2 
gene transcription and the names of the puta- 
tive  nuclear  binding proteins  are  indicated. 
Numbers indicate the base pair positions rela- 
tive to the transcription start site. (B) Delinea- 
tion of Dex-responsive elements by analysis of 
wild-type I1:2 enhancer ([-575 to +47 bp]I1: 
2-CAT or [-317 to +47 bp]IL-2-CAT),  or mu- 
tants carrying the internal deletions indicated 
(A [-317/-286]Ib2-CAT, A [-279/-263111: 
2-CAT,  A[-255/-217]IL-2-CAT,  A[-208/ 
- 174]I1:2-CAT,  A[ - 160/- 150]IL-2-CAT, 
A[- 116/- 88]IL-2-CAT,  A[-82/- 73]I1:2- 
CAT) activating transcription of the CAT gene. 
4/~g of the indicated plasmids plus 1/zg of 
wild-type GR expression vector and 1 #g of 
pCHl10 were cotransfected into Jurkat cells, 
and 24 h later cells were treated with TPA and 
calcium ionophore as indicated in Materials  and 
Methods in the absence or in the presence of 
1/~M of DEX. The shaded and solid bars give 
the TPA/caleium ionophore-induced  CAT ac- 
tivities (assayed 24 h later) in untreated (-DEX) and Dex-treated (+DEX) cells, respectively, expressed as the average (_+ SE) percent activity relative 
to the TPA/calcium ionophore--activatable [-575 to  +47 bp]Ib2-CAT expression (2,550  +  150 pmol/h/mg of protein and 30  +  5 pmol/h/mg of 
protein in the presence and in the absence, respectively, of TPA/A23187). 
previous reports (14), Fig. 2 shows that the main regulatory 
sequences of the II.-2 gene are located in the  -317 to  + 47 
bp region. The strongest enhancer c/s elements of the II-2 
promoter map to the the NFAT, the proximal AP-l-like, and 
the proximal and the distal octamer motifs, since significantly 
decreased transcriptional activity was observed in constructs 
carrying internal deletion of those sequences. As previously 
reported (14), these deletion mutants still display transcrip- 
tional activity due to the function of isolated or cooperating 
residual c/s elements. The Dex-responsive region was restricted 
to the  -317 to  +47 fragment of the Ib2 enhancer,  since 
the (-317/+47)  IL-2-CAT expression  vector was inhibited 
to a similar extent as the (-575/+47)  IL-2-CAT construct 
by Dex treatment (Fig. 2). Impairment of the Dex-induced 
inhibition of the transcriptional activity,  as compared with 
the wild-type  -317/+47  bp enhancer,  was  only observed 
in the mutants carrying limited (15 and 10 bp, respectively) 
and  specific sequence  deletions disrupting the  NFAT  site 
(A[- 279/- 263]II.-2-CAT) and the proximal AP-l-like motif 
(A[-160/-150)Ib2-CAT)  (Fig.  2),  and  interrupting the 
binding of the cognate factors  (14). This suggests that cis 
elements containing  both NFAT and proximal AP-l-like motifs 
are responsive  to the inhibitory action of Dex. 
The IL,2-proximal AP-l-like Motif Binds an AP-1 Complex 
Containing  fos Protein in Jurkat Cells.  The deletion experi- 
ments described in Fig. 2 show that an AP-l-like motif ap- 
pears to be involved in GR-mediated negative regulation. Since 
GR has been shown to inhibit the transcriptional activity 
of AP-1 c/s elements by interfering with los protein, a com- 
ponent of the AP-1 factor-DNA binding activity (41), we 
wanted to determine whether los was present in the com- 
Figure 3.  Gel retardation assay  of nuclear extracts from untreated Jurkat 
cells or cells treated for 2 h with TPA (30 ng/ml) and A23187 (1 ~g/ml). 
Nuclear extracts (5 #g) were incubated as described  in Materials  and Methods 
with a labeled (-160 to  -139) I1:2-AP-1 probe in the absence or in the 
presence of a 10-fold or a 100-fold excess of either unlabeled wild-type 
I1:2-AP-1 or mutated AP-I-ml (ml) or AP-I-m2 (m2) oligonucleotides. 
AP-I-ml and AP-I-m2 carry mutations inside and outside the AP-1 target 
sequence, respectively.  The figure also shows the nuclear factor-DNA com- 
plex formed in the presence of antibody (Ab) against los or ~-galactosidase 
(/~-gal) antigens. Arrowhead indicates the inducible AP-1 protein-DNA 
complex. 
640  Interleukin 2 Enhancer Regulation by Glucocorticoid  Receptor Figure 4.  Effect  of Dex treatment  on the ability  of multimers of I1.-2 
c/s dements to activate  the tk promoter-CAT  transcriptional  unit. 4 #g 
of the indicated  IL-2-derived  tk-CAT  expression  vectors  and pGALV-AP-1- 
CAT were  transfected  into  Jurkat cells. After  24 h, cells were treated  with 
TPA/calcium ionophore and Dex as indicated  in Fig. 2. Results are ex- 
pressed as the average (•  SE) fold  increase of the CAT activity  observed 
in TPA/calcium  ionophore-treated  relative to untreated cells in the ab- 
sence (-DEX)  or in the presence (+DEX) of 1 #M Dex treatment. 
plex formed by the II.,2-proximal AP-l-like motif and nu- 
clear extract from phorbol ester/calcium ionophore--activated 
Jurkat cells. Fig. 3 shows that an antibody against los protein 
was able to inhibit the binding of nuclear factor(s)  to the 
Ib2 AP-l-like motif, while an unrelated antibody was uneffec- 
tive,  suggesting the presence of los or a fos-rdated antigen 
in that complex. Oligonucleotides carrying mutations within 
the AP-1 target sequence (ml) do not compete for the binding 
of nuclear factor to the wild-type motif, while a mutation 
outside the AP-1 sequence (m2) resulted in an actively com- 
peting oligonucleotide (Fig. 3). These data provide evidence 
that a typical AP-1 factor binds to the IL-2-proximal  AP-1 
motif in Jurkat cells. 
Dex Impairs the Synergism between the NFAT and AP-1 
Motifs.  To further delineate the cis elements responsive  to 
Dex, we studied the ability of the drug to affect the TPA/cal- 
cium ionophore-activated transcription of the tk promoter- 
driving CAT gene directed by multimers of the NFAT, prox- 
imal octamer, distal and proximal AP-1, and NFkB binding 
sites. Fig. 4 shows that the transcriptional activity of NFAT 
and octamer motifs were significantly enhanced by TPA and 
calcium ionophore treatment. In contrast, neither NFkB nor 
AP-1  dements  were  significantly enhanced by  TPA  and 
A23187. The incapability of the NFkB-CAT construct to re- 
spond to TPA/A23187-mediated  activation together with the 
failure of the internal deletion of the NFkB site to decrease 
the transcriptional activity of the whole enhancer (reference 
14 and Fig. 2) suggest that this dement is not functional. 
This is however in contrast with the reported decreased en- 
hancer activity caused by point mutations of the NFkB site 
affecting its factor binding capability (15) and by the ability 
of NFkB concatemers to enhance transcription from heterol- 
ogous promoter in response  to phorbol ester and PHA in 
murine EL4 calls (17). All of  these data, taken together, sug- 
gest that determined steric configuration of the II.-2 enhancer 
and/or cell-specific  microenvironment is required for the proper 
functioning of the NFkB element. In contrast to the 11.-2- 
AP-1-CAT  construct, another AP-1 motif derived from the 
GALV LTR (GALV-AP-1-CAT) was significantly enhanced 
by TPA and calcium ionophore (Fig. 4). Dex was not able 
to inhibit the expression  of any of the IL-2-derived  multi- 
meric constructs either in the absence or in the presence of 
TPA and calcium ionophore, except  for the  -575  to  +47 
bp region of the 1I.-2 enhancer driving the CAT gene through 
the tk promoter (p[+47/-575]tk-CAT)  (Fig.  4).  Interest- 
ingly, the GALV-AP-1-CAT expression was significantly in- 
hibited by Dex, as previously reported (10). In spite of the 
involvement of the NFAT site in mediating Dex action on 
Figure 5.  DEX inhibits the synergism  between the 
NFAT and the AP-1 motifs  in directing  transcription  of 
CAT gene  from  the tk promoter. Different  combinations 
of  synthetic  oligonudeotides  spanning the NFAT  and prax- 
imal AP-1 motifs  (indicated in a) were cloned into the 
BamHl site in front of the fusion  gene tk-CAT. (a) The 
sequences of the NFAT and AP-1 oligonudeotides  corre- 
sponding to the concatemers  shown  in the fast, second, 
and fourth rows of b and of the combined NFAT-AP-1 
oligonudeotide  indicated  in the third  row. Lowercase  letters 
indicate the BamHI  and Bglll linker  restriction sites. 4 
#g of the indicated  tk-CAT  constructs  plus 1/~g  of  wild- 
type  GR expression  vector  and 1/~g  of  pCHl10 were  trans- 
fected into  Jurkat cells, and 24 h later cells were treated 
as indicated  in Fig. 2. (b) Results are expressed as the av- 
enge (•  SE) fold  increase of the CAT activity  observed 
in TPA/calcium  ionophore-treated  relative to untreated 
cells in the absence (-DEX) or in the presence (+DEX) 
of 1/~M Dex treatment. 
641  Vacca et al. the intact I1--2 enhancer suggested by experiments shown in 
Fig. 2 using internal deletion mutants, hormone was unable 
to inhibit the transcriptional activity of homo-oligomers of 
this c/s element (Fig. 4).  This suggests that Dex does not 
affect the transcriptional activity of the NFAT motif per se, 
implying that the hormone inhibitory action requires  the 
cooperation of other c/s elements or sequences adjacent  to 
the NFAT site that are lost or disrupted in the NFAT-tk-CAT 
construct. Since deletion of the proximal AP-1 motif also im- 
paired Dex sensitivity of the I1.2 enhancer (Fig. 2), we specu- 
lated that cooperativity between the NFAT and AP-1 sites 
was required for conferring Dex-induced downregulation of 
the I1-2 promoter. For this purpose, we first tested the hy- 
pothesis that transcriptional cooperativity would exist be- 
tween the two c/s elements by constructing CAT vectors con- 
taining different combinations of NFAT and proximal AP-1 
elements. Fig. 5 shows that introduction of two AP-l-like 
elements 5' to the NFAT site does not further enhance the 
capability of the NFAT motif to respond to TPA and cal- 
cium ionophore. In contrast, although the proximal AP-1 
A 
3  L(NFAT)tk.CAT  m 
31(NFATm)tk-CAT 
3:(kPt)tk-C^T  I 
3x(APImDtk-CAT  I 
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2x(NFAT-APt  )tk~AT I 
2~NFATm-API)tk-CAT  I 
2xlNFAT-AP1  m  I )dL-CAT 
7Jt(NFAT-API m2)tk-CAT 
0 
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Figure 6. 
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5'-TAAAGAAAGGAGaAAAAAaTtTTTaATACAG AAG-3' 
5'-AAATTCCAAAGAGTCATCAGAA-3' 
5'-AAATTCCAAAGAactgTCAGAA-3' 
5'-gggcTCCAAAGAGTCATCAGAA-3' 
Mutations of NFAT and AP1 binding sites abolish transcrip- 
tional cooperativity and Dex-regulation.  Different combinations of syn- 
thetic oligonucleotides spanning  the wild-type (NFAT and proximal AP-1) 
or mutated (NFATm, AP-I-ml and AP-I-m2) motifs were constructed as 
described in Fig. 5. (B) The sequence of the oligonucleotide used. Lower- 
case letters indicate the mutated nueleotides. The AP-1 motif is under- 
lined. 4/zg of the indicated tk-CAT constructs plus 1/zg of wild-type 
GR expression vector and 1/~g of pCHl10 were transfected into Jurkat 
cells, and 24 h later cells were treated as indicated in Fig. 2. (A) Results 
are expressed as the average (+_ SE) fold increase of the CAT activity ob- 
served in TPA/calcium ionophore-treated  relative to untreated cells in the 
absence (+DEX) or in the presence (+DEX) of 1/~M Dex treatment. 
site is unable to be significantly activated by TPA and A23187 
on its own, a dimer of an ohgonucleotide spanning a NFAT 
site and a proximal AP-1 motif in the 5' to 3' configuration 
shows a significant  increase in the capability  to respond to 
TPA/A23187 with respect to the NFAT-alone tk-CAT con- 
struct (Fig. 5). To study whether the transcriptional syner- 
gism between the two elements involved sequences binding 
NFAT and AP-1 factors, respectively, we introduced four base 
pair substitutions in the NFAT and AP1 motifs (NFATm and 
APlml, respectively), which specifically  interrupted the factor 
binding ability (Fig. 3 and references 20 and 42). Mutation 
of the NFAT target sequence (NFATm) significantly reduced 
the ability of either enhancing the TPA/A23187-induced CAT 
transcription from NFAT homo-oligomers (3xNFATm-tk- 
CAT) or synergizing with wild-type AP-1 (3x[NFATm-AP- 
1]tk-CAT)  (Fig. 6). Similarly, mutation of the AP-1 target 
sequence (AP-lml) abolished the synergism with the wild- 
type NFAT element (2x[NFAT-AP-lml]tk-CAT) (Fig.  6), 
while mutation outside the AP-1 target sequence (AP-lm2), 
which did not  affect the binding of nuclear factor from 
TPA/A23187-induced cells (Fig. 3 and reference 20), was un- 
able to do so (2x[NFAT-AP-lm2]tk-CAT, Fig. 6). All of these 
data taken together suggest that the proximal AP-1 motif 
synergizes  with the NFAT site as far as its transcriptional 
activation by TPA and A23187 is concerned. Furthermore, 
this also suggests that this cooperativity requires  a specific 
steric configuration of the AP-1 element relative to the NFAT 
motif, as physiologically occurring in the intact II.-2 enhancer. 
Interestingly, the proximal AP-1 element is able to confer 
Dex-induced downregulation to the NFAT motif, since Dex 
was able to significantly  inhibit the transcriptional activity 
of (NFAT-AP-1)z-tk-CAT construct, while not affecting the 
expression of NFAT-tk-CAT (Fig. 5). Mutations specifically 
affecting the NFAT (NFATm) and AP-1 (AP-lml) binding 
sites abolished the Dex-induced downregulation of combined 
concatemers, while a mutation of the AP-1 motif outside the 
AP-1 target sequence (AP-lm2) retained the hormone sensi- 
tivity when this mutated AP-1 element was combined with 
the wild-type NFAT motif (Fig.  6). 
Discussion 
Several enhancers are known to be composed of multiple 
sequence motifs functioning cooperatively or noncooperatively 
and binding cellular trans-acting factors involved in eliciting 
the  transcriptional  machinery  (43,  44).  Genetic  analysis 
of the transcriptional enhancer of the Siminan Virus 40 al- 
lowed the identification of distinct classes of enhancer motifs 
(enhansons)  characterizing multiple levels of functional or- 
ganization (43, 45-47). Combination of isolated enhansons 
makes up enhancer function as a result of the synergistic ac- 
tion of the single c/s elements provided of strong (type I, 
III,  and IV protoenhancers) or very weak (type II proto- 
enhancer) enhancer activity on their own (45, 46). The IL-2 
enhancer is also composed of isolated cis elements binding 
cognate trans-acting  factors and cooperating in making up 
the overall enhancer activity in response to the multiple signals 
arising from the extracellular microenvironment (14-20). In- 
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decreases the overall enhancer activity of the  -317 to  +47 
bp II.-2 region leaving however a transcriptional activity due 
to the presence of residual c/s dements (14, 15,  19). How- 
ever, how the IL-2 enhamons cooperate each other and whether 
such a cooperativity represents a level at which transcriptional 
modulation by extracdlular agents might occur is still poorly 
understood. These questions have been spedfically addressed 
in this paper. Here we show that the IL-2 enhancer is com- 
posed of at Ieast a type II proto-enhancer unit represented 
by the combination of a strong enhancer dement on its own 
(the NFAT site) and a very weak one (the proximal AP-1 
motif). This is supported by the observation that, in spite 
of being a highly synergistic dement in the whole enhancer, 
as demonstrated by the decrease of the overall enhancer ac- 
tivity caused by its internal deletion (reference 14 and Fig. 
2),  the AP-1 motif is different in its intrinsic enhancer ac- 
tivity from the NFAT dement. In fact, while tandem repeats 
of the NFAT site are provided of transcriptional c/s-regulatory 
activity on their own, homo-oligomers of the AP-1 motif 
are not. Nevertheless,  the AP-1 motif combined with the 
NFAT site synergistically generates enhancer activity higher 
than that of NFAT homo-oligomers. Interestingly, a specific 
stereoalignment or spacing between the two dements ap- 
pears to be required for optimal cooperativity, since no syn- 
ergism was observed when tandem repeats of the AP-1 motif 
were introduced 5' to the NFAT site instead of 3; as physio- 
logically occurs in the II.-2 enhancer. 
An interesting question that rose from the combinatorial 
functional organization of the Ib2 enhancer deals with the 
possibility that a hierarchical  order of preferential  coopera- 
tivities among selected enhansons occurs.  By studying the 
interference of the activation of the multiple c/s dements of 
the IL-2 enhancer by the GR, our results suggest that such 
a preferential cooperativity between NFAT and AP-1 dements 
does occur, since those two motifs compose a regulatory 
pathway selectively affected by the GR. Indeed, we have ob- 
served that both sequences containing the NFAT and AP-1 
motifs, when located in the physiologic genetic context of 
the whole IL-2 enhancer, are responsive to GR-mediated nega- 
tive signals and that the regulation of the isolated NFAT ele- 
ment by GR is only conferred by the involvement  of the AP-1 
motif. The molecular mechanism by which GR interferes 
with AP-1-NFAT cooperativity needs to be elucidated. Nega- 
tive regulation of gene expression by GR might be due to 
altered synthesis of specific trans-acting  factors (48-52). Such 
a mechanism does not appear to be responsible for the down- 
regulation of the Ib2 enhancer by GR, since expression of 
trans-acting  factors binding to both NFAT and AP-1 motifs 
have recently been reported to be unaffected by Dex (26). 
Synergistic action of steroid hormone receptors with homo- 
logue or heterologue trans-acting  factors has been reported 
to give rise to enhancer positive cooperativity (53, 54). Such 
a positive cooperativity is suggested to be mediated by the 
binding of the receptor to its cognate enhancer motif and 
subsequent  protein-protein  interactions  with  tram-acting 
factors and/or other components of the transcriptional ma- 
chinery. A cooperative mechanism might also account for 
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negative gene regulation by steroid receptors,  since suppres- 
sion of transcription via either receptor-mediated competi- 
tion with positive tram-acting factors for binding to overlap- 
ping c/s elements or interference with such positive factor 
function through protein-protein interaction have been re- 
ported (51, 52,  55,  56).  GR has been recently reported to 
bind to thejun/fos/AP-1 trans-acting  complex and to inhibit 
its function upon the collagenase AP-1 motif (41, 51, 52, 56). 
Dex is also able to inhibit the TPA-inducible activity of an- 
other AP-1 motif der/ved from the GALV LTR (this paper 
and reference 10). A  similar antagonism between GK and 
the AP-1 element of the Ib2 enhancer might also occur. In- 
deed, the AP-1 motif of the IL-2 enhancer has been shown 
to bind a purified AP-1 factor from HeLa cells (17). Further- 
more, coUagenase AP-1 motif and the AP-1 element of the 
IL-2 enhancer cross-compete for binding of the same set of 
phorbol ester and calcium ionophore-inducible  nuclear factors 
in Jurkat eells (21). Direct evidence that (- 160 to - 150 bp) 
ID2-AP-1 motif binds AP-1 complex in activated Jurkat cells 
is given in this work by the observation of the presence of 
los or a los-related antigen in the nuclear factor(s)-DNA com, 
plex. Mapping of the GK domains involved in the functional 
inhibition of the transcriptional activity of the IL-2 enhancer 
reveals that the NH2-terminal, COOH-terminal and DNA- 
binding domains are required for optimal repression. Require- 
ment of the same GR domains has also been described for 
the interaction with the jun/AP-1 complex in the regulation 
of the collagenase AP-1 motif (56). Although the composi- 
tion of the trans-acting factors binding to the Ib2-AP-1 motif 
and the nature of the potential interaction of the GK with 
both or either these factors and/or the cognate c/s elements 
remain to be further studied, the GR-mediated downregula- 
tion of the IL-2 c/s-regulatory sequences we have reported here 
appears to be quite peculiar. In fact, so far, GR has been de- 
scribed to interfere with the positive factor that transacts ele- 
ments provided of transcriptional activity on their own, 
resulting in a subtraction of an enhancer unit from the overall 
regulatory region (class A, C, or D enhansons; 51, 52, 55, 
56). The GR-mediated downregulation of the AP-1 motif 
reported here suggests a novel mechanism of transversal nega- 
tive regulation by steroid receptors in which receptor sensi- 
tivity is conferred to flanking cis dements provided of en- 
hancer properties on their own through cooperativity with 
a dass B enhanson (AP-1 motif), which is the presumable 
element involved in GR-mediated signals. 
Switching off or on the activity of isolated c/s dements 
so far has also been reported as the major mechanism involved 
in the modulation of the IL-2 enhancer.  For instance,  cy- 
dosporin  A  and  other  immunosuppressants that  inhibit 
peptidyt-propyl cis-trans isomerases have been shown to de- 
crease the transcriptional activity of homo-oligomers  of sdected 
IL-2 c/s elements (23-25). A similar mechanism recently has 
been reported for another member of the steroid hormone 
receptor superfamily, the retinoic acid receptor, which inhibits 
the enhancer activity of the IL-2-octamer motif (57).  Here 
we have provided evidence of a second level of modulation 
of the IL-2 enhancer function in which hormone-mediated 
decreased transcriptional activity is strictly dependent on the heterologous combination of distinct c/s elements. This would 
dramatically amplify the spectrum of agents and corresponding 
transducing molecular pathways activating defined IL-2 en- 
hansom, which would in this way be able to interfere with 
the overall IL-2 gene expression on the basis of complex com- 
binatorial modular interplays. 
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